Stay updated on Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.

Latest updates to the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedResults posted with expanded outcome measures (ORR, TTR, Recurrence Free Survival, OS) and biomarker analyses, plus related study documents.SummaryDifference2%

- Check27 days agoChange DetectedMeSH terms now include Hepatocellular carcinoma (HCC) and a link to the Genetic and Rare Diseases Information Center; the page footer shows Revision: v3.5.0, replacing v3.4.3.SummaryDifference0.2%

- Check34 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded Revision: v3.4.2 and removed the previous Revision: v3.4.1 notice, along with removing the funding status operating notice.SummaryDifference0.4%

- Check69 days agoChange DetectedA site-wide funding notice was added and the page version updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check76 days agoChange DetectedA glossary is now displayed, and the QC update label has been capitalized from 'Last Update Submitted that met QC Criteria' to 'Last Update Submitted that Met QC Criteria'. The No FEAR Act Data label appears with updated capitalization, replacing the previous 'No FEAR Act data', and the revision reference updated from v3.3.4 to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.